Discover the pioneering approach to safeguarding infant health in West Kazakhstan with our latest study on selective screening for metabolic disorders using cutting-edge tandem mass spectrometry.
– by Klaus
Note that Klaus is a Santa-like GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Selective screening for inborn errors of metabolism using tandem mass spectrometry in West Kazakhstan children: study protocol.
Zharmakhanova et al., Front Genet 2023
DOI: 10.3389/fgene.2023.1278750
Ho-ho-ho! Gather ’round, my little elves, for I have a tale from the far-off frosty lands of western Kazakhstan, where the mystery of inborn errors of metabolism (IEM) is as elusive as a reindeer in a snowstorm. The clever folks in this wintry wonderland have embarked on a quest, much like our annual journey around the globe, but instead of delivering toys, they’re aiming to deliver answers to a health conundrum!
Their sleigh, equipped with the magical LC-MS/MS method, will glide from clinic to clinic, seeking out young ones from the tender age of just one day to the sprightly age of 18 years. Their mission? To perform selective screening for hereditary metabolic diseases, a task as important as checking the list twice!
The first task on their list is to assess the burden of these metabolic disorders, much like I assess who’s been naughty or nice. They’ll be examining children at clinical risk, ensuring no stone is left unturned in their pursuit of health and happiness.
The second task, as crucial as feeding the reindeer, is to set the reference values of metabolites in the child population. They’ll be including a merry band of 750 healthy children to establish what’s normal, much like we define what’s good behavior!
The third task, as intricate as making toys, is to analyze the age distribution, prevalence, and age of onset for each identified IEM. They’ll compare their findings with tales from other populations, ensuring a story as complete as the list of children around the world.
With a twinkle in their eye, they’ll interpret the results of selective screening by comparison with the reference values established. Diagnosis will be based on clinical signs, much like I determine who’s awake, and levels of amino acids, acylcarnitines, succinylacetone, and the presence of organic acids and gene mutations in blood and urine.
An assessment of 37 inborn errors of metabolism frequencies in high-risk children will be performed, a task as detailed as decorating the Christmas tree. This research will help develop the national as selective as expanded newborn screening programs, a gift that keeps on giving!
And, my dear friends, this study was registered in the grand list of clinicaltrials.gov on the 16th of June, 2023, under the number NCT05910151. So, let’s jingle all the way to better health for the children of Kazakhstan! 🎅🔔